Literature DB >> 24329682

Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis.

Yiyu Qin1, Bingfeng Chu, Wei Gong, Jiandong Wang, Zhaohui Tang, Jun Shen, Zhiwei Quan.   

Abstract

BACKGROUND AND AIM: The biological function of tumor suppressor deleted in liver cancer 1 (DLC1) has been investigated in several types of human cancer, but its role in gallbladder cancer (GBC) is yet to be determined. In this research, we conducted in vitro and in vivo analysis to evaluate the inhibitory activities of DLC1 gene against GBC growth.
METHODS: DLC1 expression in GBC tissues and cell lines was examined by immunohistochemical staining, reverse transcription polymerase chain reaction, and Western blot assay. The in vitro and in vivo effects of ectopic DLC1 expression on cell growth were evaluated. In addition, the effects of ectopic DLC1 expression on cell cycle, apoptosis, and migration were also evaluated. The expressions of cell cycle-related and apoptosis-related proteins were examined.
RESULTS: The downregulation of DLC1 expression was a common event in GBC tissues and cell lines. Restoration of DLC1 expression in GBC-SD and NOZ cells significantly reduced cell proliferation, migration in vitro, and the ability of these cells to form tumors in vivo. Restoration of DLC1 expression arrested GBC-SD and NOZ cells in G0/G1 phase through inducing p21 in a p53-independent manner. In addition, restoration of DLC1 expression induced extrinsic and intrinsic apoptotic pathway through promoting the expressions of Fas L/FADD, Bax, cytochrome c, cleaved caspase-8, -9, -3, and cleaved poly-(ADP-ribose) polymerase and suppressing bcl-2 expression in GBC-SD and NOZ cells.
CONCLUSIONS: Our findings suggested that dysregulated expression of DLC1 is involved in proliferation and invasion of GBC cells and may serve as a potential therapeutic target.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  apoptosis; cell cycle; deleted in liver cancer 1; gallbladder cancer; gene therapy

Mesh:

Substances:

Year:  2014        PMID: 24329682     DOI: 10.1111/jgh.12486

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

2.  Sex differences in oncogenic mutational processes.

Authors:  Constance H Li; Stephenie D Prokopec; Ren X Sun; Fouad Yousif; Nathaniel Schmitz; Paul C Boutros
Journal:  Nat Commun       Date:  2020-08-28       Impact factor: 14.919

3.  Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.

Authors:  Deepika Singh; Amisha Bharti; Dipanjan Biswas; Mallika Tewari; Amrita Ghosh Kar; Mumtaz Ahmed Ansari; Sunita Singh; Gopeshwar Narayan
Journal:  J Gastrointest Cancer       Date:  2021-01-08

4.  DLC1 Is a Prognosis-Related Biomarker Correlated With Tumor Microenvironment Remodeling in Endometrial Carcinoma.

Authors:  Yalan Wu; Li-E Zheng; Shumin Chen; Chengyu Lv; Yuxiu Huang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

5.  MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.

Authors:  Guang-jun Zhang; Jian-shui Li; He Zhou; Hua-xu Xiao; Yu Li; Tong Zhou
Journal:  J Exp Clin Cancer Res       Date:  2015-07-30

6.  Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.

Authors:  Yuqi Su; Li Lin; Jingwen Zhang; Yaqi Jiang; Changqie Pan; Li Sun; Jiangman Duan; Wangjun Liao
Journal:  Mol Med Rep       Date:  2015-08-03       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.